HOME

TEAM

MEDIA

ESG

INVESTMENTS

CONTACT

FUNDS

ENVIRONMENTAL, SOCIAL AND GOVERNANCE STATUS

Óskare Capital is ESG Compatible

Óskare Capital management team’s personal commitment to the environment is rooted deep in their experience as venture capital investors and entrepreneurs in the cleantech and circular economy sectors.

Created by potrace 1.15, written by Peter Selinger 2001-2017

Óskare Fund I can also invest in companies that will optimise the use of resources in synthetic and agricultural processes. Additionally, the fund can explore opportunities in waste valorization such as bioplastics, composite materials, fabrics, pulp and paper and other potential streams for waste reduction.

There is a history of self-medication with cannabinoids which can present risks to individuals. We champion medicines and therapies with full regulatory approval for the benefit of patients.

The companies that Óskare Capital invest in are developing products and/or services that focus on health and wellness that seek to improve patients' quality of life.

ÓSKARE FUND I IS ESG COMPATIBLE

Óskare Capital will avoid investing in companies pertaining to, or involving, business activities and sectors that are illegal or could lead to reputational risks. Our strategy involves a proactive consideration of ESG factors in investments.

During our investment selection and due-diligence process we will assess each investment opportunity using the ESG criteria:

  • Environmental and agricultural risks
  • Social risk: Serious infringement of relevant international standards or agreements relating to human rights, labor and employment, bribery and corruption; tax haven countries; drug abuse, money laundering
  • Governance:
    • The exercise of fiduciary duty: it includes the duty to treat each investor equitably and fairly and to act in the best interest of the Funds we manage
    • The advisory board role in corporate compliance programs, resolution of conflicts of interest issues
    • Tax avoidance: this will never be a motivation for investments or behavior in governing bodies
    • Executive compensations: fairly determined and reviewed regularly to align the interests of management and the investors

ENDOCANNABINOID THERAPIES ARE ESG COMPATIBLE

Large institutional investors with stringent ESG guidelines are now investing in this sector:

  • In 2018, the Fourth Swedish National Pension Fund (AP4) with a fund capital of SEK 391 billion as of June 30, 2019 removed medical cannabis from its exclusion list
  • In June 2019, the Commissioner of the Church of England (with an endowment of £8.4 billion) recently announced that it will consider investing in cannabis companies with a sole medical purpose
  • Vanguard Group, Morgan Stanley Canada, and BlackRock Institutional Trust Company are a few of the institutional investors with exposure to the sector
  • In 2018, Canada’s Public Sector Pension Investment Board (PSP) and the California Public Employees Retirement System (CalPERS) acquired shares in medical cannabis producers
  • 13 US State Pension Funds* invested in Innovative Industrial Properties (NYSE: IIPR) that has 1.8 million square feet of space that’s leased to medical marijuana operators in states that have legalized cannabis